Published in Hypertension on January 01, 1992
Mechanisms of glucose homeostasis after Roux-en-Y gastric bypass surgery in the obese, insulin-resistant Zucker rat. Ann Surg (2009) 1.20
Renal autoregulation in health and disease. Physiol Rev (2015) 1.18
Relation of serum lipids and lipoproteins with progression of CKD: The CRIC study. Clin J Am Soc Nephrol (2014) 1.10
Ileal interposition improves glucose tolerance and insulin sensitivity in the obese Zucker rat. Am J Physiol Gastrointest Liver Physiol (2010) 1.07
Development of a sleeve gastrectomy weight loss model in obese Zucker rats. J Surg Res (2008) 0.99
The prostacyclin analog beraprost sodium ameliorates characteristics of metabolic syndrome in obese Zucker (fatty) rats. Diabetes (2010) 0.95
The carbonyl scavenger carnosine ameliorates dyslipidaemia and renal function in Zucker obese rats. J Cell Mol Med (2010) 0.95
Roux-en-Y gastric bypass alters small intestine glutamine transport in the obese Zucker rat. Am J Physiol Gastrointest Liver Physiol (2009) 0.94
Blunted temporal activity of microvascular perfusion heterogeneity in metabolic syndrome: a new attractor for peripheral vascular disease? Am J Physiol Heart Circ Physiol (2012) 0.91
Diabetes, obesity and erectile dysfunction: field overview and research priorities. J Urol (2009) 0.90
Effect of rosiglitazone on bone quality in a rat model of insulin resistance and osteoporosis. Diabetes (2011) 0.89
Increase of adiponectin receptor gene expression by physical exercise in soleus muscle of obese Zucker rats. Eur J Appl Physiol (2006) 0.86
Obese and lean Zucker rats demonstrate differential sensitivity to rates of food reinforcement in a choice procedure. Physiol Behav (2012) 0.84
Pharmacodynamic characterization of insulin on MDMA-induced thermogenesis. Eur J Pharmacol (2009) 0.83
Arginase promotes endothelial dysfunction and hypertension in obese rats. Obesity (Silver Spring) (2014) 0.82
Dyslipoproteinemia and impairment of renal function in diabetic kidney disease: an analysis of animal studies, observational studies, and clinical trials. Rev Diabet Stud (2013) 0.81
Distinct temporal phases of microvascular rarefaction in skeletal muscle of obese Zucker rats. Am J Physiol Heart Circ Physiol (2014) 0.80
Metabolic syndrome, chronic kidney disease, and cardiovascular disease: a dynamic and life-threatening triad. Cardiol Res Pract (2011) 0.80
The effect of chronic candesartan therapy on the metabolic profile and renal tissue cytokine levels in the obese Zucker rat. Mediators Inflamm (2010) 0.79
Metabolic syndrome and chronic kidney disease. Indian J Nephrol (2008) 0.79
Upregulation of orexin receptor in paraventricular nucleus promotes sympathetic outflow in obese Zucker rats. Neuropharmacology (2015) 0.78
Preventive effect of taurine on experimental type II diabetic nephropathy. J Biomed Sci (2010) 0.78
Vasopeptidase inhibition attenuates proteinuria and podocyte injury in Zucker diabetic fatty rats. Naunyn Schmiedebergs Arch Pharmacol (2007) 0.78
Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes. Br J Pharmacol (2014) 0.77
Effects of xanthine oxidase inhibition with febuxostat on the development of nephropathy in experimental type 2 diabetes. Br J Pharmacol (2016) 0.77
Protective effects of antioxidant-fortified diet on renal function and metabolic profile in obese Zucker rat. Endocrine (2008) 0.77
Pepsin Egg White Hydrolysate Ameliorates Obesity-Related Oxidative Stress, Inflammation and Steatosis in Zucker Fatty Rats. PLoS One (2016) 0.76
Chronic NF-κB blockade improves renal angiotensin II type 1 receptor functions and reduces blood pressure in Zucker diabetic rats. Cardiovasc Diabetol (2015) 0.75
Diminished neurogenic femoral artery vasoconstrictor response in a Zucker obese rat model: differential regulation of NOS and COX derivatives. PLoS One (2014) 0.75
Identification of a possible role for atrial natriuretic peptide in MDMA-induced hyperthermia. Toxicol Lett (2011) 0.75
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med (2001) 22.32
Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet (1995) 4.06
Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med (1989) 2.94
Identification of the CD4(+) T cell as a major pathogenic factor in ischemic acute renal failure. J Clin Invest (2001) 2.79
Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis (1999) 2.38
Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother (1984) 2.09
Definition of health promotion: Part III: Expanding the definition. Am J Health Promot (1989) 1.95
The glomerular mesangium. Kidney Int (1980) 1.83
Experimental pyelonephritis. XIV. Pyelonephritis in normal mice produced by inoculation of E. coli into the bladder lumen during water diuresis. Yale J Biol Med (1967) 1.67
The laryngeal mask airway and positive-pressure ventilation. Anesthesiology (1994) 1.62
Mechanism of Escherichia coli alpha-hemolysin-induced injury to isolated renal tubular cells. Am J Pathol (1987) 1.57
Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med (1993) 1.54
Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. Ann Intern Med (1994) 1.44
Antimicrobial treatment of peritonitis associated with continuous ambulatory peritoneal dialysis. Perit Dial Int (1991) 1.42
A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine (2001) 1.41
Bacterial growth and killing in chronic ambulatory peritoneal dialysis fluids. J Clin Microbiol (1984) 1.36
The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst (2000) 1.35
Peritoneal macrophages and opsonins: antibacterial defense in patients undergoing chronic peritoneal dialysis. J Infect Dis (1983) 1.35
Cefotaxime and desacetyl cefotaxime kinetics in renal impairment. Clin Pharmacol Ther (1985) 1.34
Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? Lancet (1996) 1.34
Opsonic deficiency of peritoneal dialysis effluent in continuous ambulatory peritoneal dialysis. Kidney Int (1984) 1.29
Proteinuria is a risk factor for mortality over 10 years of follow-up. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Kidney Int Suppl (1997) 1.28
Renal injury of diet-induced hypercholesterolemia in rats. Kidney Int (1990) 1.21
Ethylene glycol poisoning: pharmacokinetics during therapy with ethanol and hemodialysis. N Engl J Med (1981) 1.21
Gas leak and gastric insufflation during controlled ventilation: face mask versus laryngeal mask airway. Can J Anaesth (1998) 1.20
Current concepts in the management of peritonitis in patients undergoing continuous ambulatory peritoneal dialysis. Rev Infect Dis (1987) 1.19
Survival and rehabilitation of patients on home hemodialysis. Five years' experience. Ann Intern Med (1973) 1.13
Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res (1988) 1.13
Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int (1988) 1.09
Opioid-mediated suppression of interferon-gamma production by cultured peripheral blood mononuclear cells. J Clin Invest (1987) 1.09
Intracellular survival of Candida albicans in peritoneal macrophages from chronic peritoneal dialysis patients. Am J Kidney Dis (1986) 1.08
Enhancement of endotoxin-induced isolated renal tubular cell injury by toxic shock syndrome toxin 1. Am J Pathol (1986) 1.04
Incidence and type of infections occurring in 445 chronic hemodialysis patients. Trans Am Soc Artif Intern Organs (1977) 1.03
Recent advances in statins and the kidney. Kidney Int Suppl (1999) 1.01
Disposition of gabapentin in anuric subjects on hemodialysis. J Clin Pharmacol (1995) 0.99
Glomerular hemodynamic and structural alterations in experimental diabetes mellitus. FASEB J (1988) 0.98
Opioid peptides rapidly stimulate superoxide production by human polymorphonuclear leukocytes and macrophages. Endocrinology (1985) 0.98
Opioid-mediated suppression of cultured peripheral blood mononuclear cell respiratory burst activity. J Immunol (1987) 0.98
Unilateral Shwartzman reaction: cortical necrosis in one kidney following in vivo perfusion with endotoxin. Kidney Int (1977) 0.98
Effects of genetic obesity on renal structure and function in the Zucker rat. J Lab Clin Med (1985) 0.96
Pharmacokinetics of tazobactam M1 metabolite after administration of piperacillin/tazobactam in subjects with renal impairment. J Clin Pharmacol (1994) 0.96
Hyperlipidemia and the progression of renal disease. Am J Clin Nutr (1988) 0.96
Role of hypertension in progressive glomerular immune injury. Hypertension (1985) 0.96
Relationship among altered glomerular barrier permselectivity, angiotensin II, and mesangial uptake of macromolecules. Lab Invest (1985) 0.95
Protein binding of disopyramide and elevated alpha-1-acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant recipients. Am J Nephrol (1985) 0.95
Effect of lovastatin on the development of polycystic kidney disease in the Han:SPRD rat. Am J Kidney Dis (1995) 0.95
Early glomerular changes in rats with dietary-induced hypercholesterolemia. Am J Kidney Dis (1995) 0.93
Cholesterol-lowering effects of calcium carbonate in patients with mild to moderate hypercholesterolemia. Arch Intern Med (1992) 0.92
Lovastatin but not enalapril reduces glomerular injury in Dahl salt-sensitive rats. Hypertension (1992) 0.92
Lipids and progressive glomerulosclerosis. A model analogous to atherosclerosis. Am J Nephrol (1988) 0.92
Opsonization of Legionella pneumophila in human serum: key roles for specific antibodies and the classical complement pathway. Immunology (1985) 0.91
Small molecule selectin ligand inhibition improves outcome in ischemic acute renal failure. Kidney Int (2001) 0.90
Effects of genetic obesity on renal structure and function in the Zucker rat. II. Micropuncture studies. J Lab Clin Med (1985) 0.90
Polyamino acid enhancement of bacterial phagocytosis by human polymorphonuclear leukocytes and peritoneal macrophages. Infect Immun (1984) 0.89
Lovastatin retards the progression of established glomerular disease in obese Zucker rats. Am J Kidney Dis (1993) 0.89
Central role of the transcription factor nuclear factor-kappa B in mesangial cell production of chemokines. Contrib Nephrol (1997) 0.88
Adriamycin-induced chronic proteinuria: a structural and functional study. J Lab Clin Med (1985) 0.88
Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest (1993) 0.87
Renal cell cytokine production stimulates HIV-1 expression in chronically HIV-1-infected monocytes. Kidney Int (1998) 0.87
Antimicrobial activities of dialysate-elicited and resident human peritoneal macrophages. Infect Immun (1985) 0.87
Forces shaping the future of health promotion. Am J Health Promot (2001) 0.87
Lipid abnormalities in end stage renal disease. Nephrol Dial Transplant (1998) 0.87
The relationship between modifiable health risks and future medical care expenditures: the Korea Medical Insurance Corporation (KMIC) Study. Am J Health Promot (2001) 0.86
Cefsulodin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother (1983) 0.86
Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: effects of oxidation and modulation by lovastatin. Biochem Biophys Res Commun (2000) 0.86
Mononuclear phagocytic system stimulation. Protective role from glomerular immune complex deposition. J Lab Clin Med (1981) 0.86
Hyperlipidemia in the nephrotic syndrome. N Engl J Med (1990) 0.86
Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats. Am J Kidney Dis (1998) 0.85
Teicoplanin pharmacokinetics in patients undergoing continuous ambulatory peritoneal dialysis after intravenous and intraperitoneal dosing. Antimicrob Agents Chemother (1989) 0.85
Lovastatin inhibits lipopolysaccharide-induced NF-kappaB activation in human mesangial cells. Nephrol Dial Transplant (1996) 0.85
Impaired mesangial clearance of macromolecules in rats with chronic mesangial ferritin-antiferritin immune complex deposition. Lab Invest (1980) 0.85
The central role of nuclear factor-kappa B in mesangial cell activation. Kidney Int Suppl (1999) 0.85
Perinephric abscess in patients with polycystic kidney disease undergoing chronic hemodialysis. Nephron (1979) 0.85
Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure. Kidney Int (2001) 0.85
Determinants of glomerular filtration and plasma flow in experimental diabetic rats. J Lab Clin Med (1981) 0.85
Lipids and progressive renal disease: the cardio-renal link. Am J Kidney Dis (1999) 0.84
Risk factors for nephropathy and cardiovascular disease in diabetic Northern Minnesota American Indians. Clin Nephrol (1996) 0.84
The national epidemic of chronic kidney disease. What we know and what we can do. Postgrad Med (2001) 0.84
Glomerular mesangium: its function and relationship to angiotensin II. Am J Med (1985) 0.83
Electrical conductivity and its use in estimating an equivalent pore size for arterial endothelium. Am J Physiol (1986) 0.83
Lipophilic statins induce apoptosis of human vascular smooth muscle cells. Kidney Int Suppl (1999) 0.83
Oxidative modification of low-density lipoproteins by mesangial cells. J Am Soc Nephrol (1993) 0.83
Effects of reduced renal mass on tissue lipids and renal injury in hyperlipidemic rats. Kidney Int (1989) 0.82
Definition of health promotion. Am J Health Promot (1986) 0.82